Allogenic stem cell transplantation for children with advanced MDS:: results from the EWOG-MDS study group employing a pre-transplant preparative regimen with busulfan, cyclophosphamide and melphalan

被引：0
|
作者：
Niemeyer, CM
Zecca, M
Korthoff, E
Duffner, U
Zintl, F
Ebell, W
Stary, J
Dillo, D
Bader, P
Peters, C
Schmugge, M
Sedlacek, P
van Heuvel, M
Bergsträsser, E
Trebo, M
Nölke, P
Locateffl, F
机构：
来源：
BONE MARROW TRANSPLANTATION | 2005年 / 35卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 44 条
  • [21] Busulfan, cyclophosphamide and melphalan is an effective preparative regimen for children with acute myeloid leukemia given allogeneic hematopoietic stem cell transplantation in 1st complete remission
    Locatelli, F
    Zecca, M
    Pession, A
    Lanino, E
    Rondelli, R
    Messina, C
    Fagioli, F
    Ripaldi, M
    Andolina, M
    Uderzo, C
    BONE MARROW TRANSPLANTATION, 2003, 31 : S24 - S24
  • [22] Prospective analysis of prognostic pre-transplant factors in MDS primarily treated by allogeneic hematopoietic stem cell transplantation: a study on behalf of the MDS subcommittee of the Chronic Malignancies Working Party of the EBMT
    Cremers, E. M.
    de Witte, T.
    van Biezen, A.
    Knodler, E.
    Finke, J.
    Beelen, D.
    Socie, G.
    Nagler, A.
    Kobbe, G.
    Volin, L.
    Gedde-Dahl, T.
    Sierra, J.
    Beguin, Y.
    Sucak, G.
    Ljungman, P.
    Anagnostopoulos, A.
    Robin, M.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S302 - S302
  • [23] Busulfan, cyclophosphamide and melphalan is an effective preparative regimen for children with acute myeloid leukemia given allogeneic hematopoietic stem cell transplantation in 1st complete remission.
    Locatelli, F
    Zecca, M
    Pession, A
    Lanino, E
    Rondelli, R
    Messina, C
    Fagioli, F
    Ripaldi, M
    Andolina, M
    Uderzo, C
    BLOOD, 2002, 100 (11) : 852A - 852A
  • [24] Busulfan and melphalan as a preparative regimen for children with hematological malignancy undergoing allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-matched sibling.
    Watanabe, H
    Watanabe, T
    Suzuya, H
    Kaneko, M
    Onishi, T
    Wakata, Y
    Okamoto, Y
    Kawano, Y
    Takaue, Y
    Kuroda, Y
    BLOOD, 2003, 102 (11) : 426B - 427B
  • [25] A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS
    Tamari, Roni
    Sheetal, Sheetal Ramnat
    Kuk, Deborah
    Papadopoulos, Esperanza B.
    Jakubowski, Ann A.
    Boulad, Farid
    Small, Trudy N.
    Kernan, Nancy A.
    Perales, Miguel A.
    Koehne, Guenther
    Ponce, Doris M.
    Devlin, Sean
    Goldberg, Jenna D.
    Young, James W.
    Giralt, Sergio A.
    O'Reilly, Richard J.
    Castro-Malaspina, Hugo R.
    BLOOD, 2012, 120 (21)
  • [26] Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
    Cremers, E. M. P.
    van Biezen, A.
    de Wreede, L. C.
    Scholten, M.
    Vitek, A.
    Finke, J.
    Platzbecker, U.
    Beelen, D.
    Schwerdtfeger, R.
    Volin, L.
    Harhalakis, N.
    Blijlevens, N.
    Nagler, A.
    Kroeger, N.
    de Witte, T.
    ANNALS OF HEMATOLOGY, 2016, 95 (12) : 1971 - 1978
  • [27] Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
    E. M. P. Cremers
    A. van Biezen
    L. C. de Wreede
    M. Scholten
    A. Vitek
    J. Finke
    U. Platzbecker
    D. Beelen
    R. Schwerdtfeger
    L. Volin
    N. Harhalakis
    N. Blijlevens
    A. Nagler
    N. Kröger
    T. de Witte
    Annals of Hematology, 2016, 95 : 1971 - 1978
  • [28] The Results of Allogeneic Hematopoietic Stem Cell Transplantation from HLA-haploidentical Donor with post-transplant Cyclophosphamide Regimen in Children
    Burya, Alexandra
    Kirgizov, Kirill
    Nikolaeva, Yulia
    Konstantinova, Veronica
    Pristanskova, Ekaterina
    Sidorova, Natalia
    Mezenceva, Anastasia
    Olhova, Ludmila
    Blagonravova, Oxana
    Filina, Olga
    Petrova, Larisa
    Skorobogatova, Elena
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 308 - 309
  • [29] LOW MORBIDITY AND MORTALITY IN A PILOT STUDY OF BUSULFAN, MELPHALAN AND TOPOTECAN AS PREPARATIVE REGIMEN FOLLOWED BY AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH HIGH RISK SOLID TUMORS (PRELIMINARY RESULTS)
    Bolotin, E.
    Pawlowska, A.
    Hitt, D.
    Andersen, C.
    Shakhnovitz, M.
    Sato, J.
    Forman, S.
    Rosenthal, J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 84 - 84
  • [30] Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
    Rambaldi, Alessandro
    Grassi, Anna
    Mico, Maria Caterina
    Busca, Alessandro
    Bruno, Benedetto
    Cavattoni, Irene
    Santarone, Stella
    Raimondi, Roberto
    Montanari, Mauro
    Milone, Giuseppe
    Chiusolo, Patrizia
    Specchia, Giorgina
    Guidi, Stefano
    Patriarca, Francesca
    Bacigalupo, Andrea
    Risitano, Antonio M.
    Saporiti, Giorgia
    Pini, Massimo
    Pogliani, Enrico Maria
    Arcese, William
    Marotta, Giuseppe
    Carella, Angelo Michele
    Nagler, Arnon
    Russo, Domenico
    Corradini, Paolo
    Alessandrino, Emilio Paolo
    Torelli, Giovanni Fernando
    Scime, Rosanna
    Mordini, Nicola
    Oldani, Elena
    Masciulli, Arianna
    Marfisi, Rosa Maria
    Bosi, Alberto
    BLOOD, 2014, 124 (21)
12345